RaQualia Pharma (TSE:4579) Total Receivables: 円1,234 Mil (As of Mar. 2026)


TSE:4579 RaQualia Pharma Inc TSE:4579
59 GF Score
Price 円491.00
GF Value 円310.01
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is RaQualia Pharma Total Receivables?

RaQualia Pharma TSE:4579 +2.72% 59 Total Receivables is 円1,234 Mil as of Mar. 2026. GuruFocus rates TSE:4579 with a GF Score™ of 59/100 and a GF Value™ of 円310.01 (Significantly Overvalued). The stock has 4 warning signs investors should review.

RaQualia Pharma's Total Receivables for the quarter that ended in Mar. 2026 was 円1,234 Mil.

RaQualia Pharma Total Receivables Related Terms

RaQualia Pharma Total Receivables Historical Data

* Premium members only.

The historical data trend for RaQualia Pharma's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RaQualia Pharma Total Receivables Chart

RaQualia Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,205.40 602.31 603.20 689.16 1,928.28

RaQualia Pharma Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,156.00 714.95 549.26 1,928.28 1,234.48
TSE:4579
59GF Score
RaQualia Pharma Inc TSE:4579
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RaQualia Pharma Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of 円1,234 Mil mean?
RaQualia Pharma (TSE:4579) has a Total Receivables of 円1,234 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on RaQualia Pharma and its competitors.
Is RaQualia Pharma's Total Receivables too high?
RaQualia Pharma's current Total Receivables is 円1,234 Mil. Overall, RaQualia Pharma has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RaQualia Pharma's Total Receivables compare to VRTX and REGN?
RaQualia Pharma's Total Receivables of 円1,234 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on RaQualia Pharma and its competitors. RaQualia Pharma's current Total Receivables is 円1,234 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaQualia Pharma stock overvalued right now?
Based on GuruFocus' analysis, RaQualia Pharma (TSE:4579) is currently considered Significantly Overvalued. The stock's GF Value™ is 円310.01, compared to a current price of 円491.00 — trading 58.4% above its estimated fair value. The current Total Receivables is 円1,234 Mil. RaQualia Pharma's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For RaQualia Pharma (TSE:4579), the current Total Receivables is 円1,234 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RaQualia Pharma (TSE:4579) Overvalued in 2026?

Based on GuruFocus' analysis, RaQualia Pharma stock appears to be overvalued. The current stock price of 円491.00 is trading 58.4% above its estimated GF Value™ of 円310.01. GuruFocus considers RaQualia Pharma to be Significantly Overvalued.

Key valuation signals for TSE:4579:

  • Total Receivables: 円1,234 Mil
  • GF Value™: 円310.01 vs. price of 円491.00 (58.4% above fair value)
  • GF Score™: 59/100 with 4 warning signs

No single metric tells the full story. See the TSE:4579 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

RaQualia Pharma Business Description

Address 1-21-19 Meieki Minami, Nakamura-ku, Nagoya, JPN, 470-2341
RaQualia Pharma Inc operates as a research and development-centered biotechnology company, generating revenue by creating the seeds for novel medicine and licensing them to pharmaceutical companies. The company manages the Sales and licensing of intellectual property for fundamental technologies related to pharmaceutical compounds and candidate compounds for clinical development. Its product portfolio includes, Tegoprazan (K-CAB), Galliprant and Elura both under Veterinary Medicines. The pipeline products include Potassium-Competitive Acid Blocker, Ghrelin Receptor Agonist, TRPM8 Blocker and 5-HT4 Agonist studied under different phases of development.
59GF Score

Get the complete analysis for TSE:4579

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円491.00
Price
円310.01
GF Value